Private, no accountPrivacy details: browsing privately, no account needed
You're browsing privately, no account needed. Your region stays in this session and your precise location is never stored.What we store
H.R. 9682 · 119th CongressIn committee

Cure Hepatitis C Act of 2026

Latest action. Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Natural Resources, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdictionA court's legal authority to hear a case: over the subject matter, the parties, and the territory.Read the full definition (opens a new tab) of the committee concerned. · July 14, 2026

Live record from Congress.gov, updated as the official record changes.
What this bill would do
Official summary · Congressional Research Service

Cure Hepatitis C Act of 2026

This bill establishes programs and requirements to provide free medications to treat hepatitis C in certain high-risk or vulnerable populations. It also establishes grants and other resources to support testing and treatment for hepatitis C. The bill provides funding for FY2027 to implement these provisions.

The Department of Health and Human Services (HHS) must enter into a five-year purchasing contract with manufacturers of drugs that treat hepatitis C so that eligible individuals may receive the drugs without cost-sharing. Eligible individuals are those diagnosed with hepatitis C who are (1) enrolled in Medicaid or the Children’s Health Insurance Program (CHIP), (2) confined to federal, state, or local correctional facilities (or were released and began treatment there), (3) uninsured, or (4) receiving health care through the Indian Health Service.

State Medicaid and CHIP programs and state and local correctional facilities may opt into the program; participation is mandatory for federal correctional facilities and the Indian Health Service.

HHS must award grants to certain entities, including states, public health organizations, and correctional facilities, to support the coordination and provision of screening, treatment, and supportive services for the affected populations.

The bill also allows Medicare beneficiaries to receive hepatitis C drugs without cost-sharing from 2028-2032.

Written by analysts at the Congressional Research Service and published on Congress.gov, not by Civibrief. Summarized at the "Introduced in House" stage on July 14, 2026. It describes the bill, it is not the legal text.

Status
Introduced
July 14, 2026
In committee
July 14, 2026
Passed a chamber
Cleared Congress
Enacted
Where this sits in the process
Common questions
Composed from the official record
Where is it in the process, and what happens next?

4 steps remain before this bill could become law.

The record's latest action, on July 14, 2026: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Natural Resources, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  1. Clearing the committees it was referred to, and being scheduled for a floor vote
  2. Passage by the House
  3. Passage by the Senate
  4. The President's signature. If the President vetoes it, two-thirds of both chambers must vote to override.
How likely is it to become law?

Civibrief does not forecast outcomes and this page has no opinion about this one. What the record supports is a base rate, which is a fact about the whole pile, not a prediction about this measure.

In the 118th Congress (2023-24), 274 of the 16,565 bills and joint resolutions introduced became law, about 1.7 percent. That count covers every measure at every stage, including the many that never left committee.

This one is not there yet: 4 steps are still outstanding, listed above.

Has anyone actually voted on it?

No. No roll call in this Congress cites this measure. That is the ordinary outcome: most measures never reach a recorded floor vote, and a committee ends most of them simply by not acting.

A vote is not the only thing that happens to a measure. Hearings, markups, and referrals are all recorded actions, and none of them is a vote of the full chamber.

Who is behind it?

Mariannette Miller-Meeks (R-IA) introduced it on July 14, 2026, and 4 members have since signed on as cosponsors.

They come from both major parties: 3 Democrats, 1 Republican.

Cosponsoring is a formal signature on the text. It is not a commitment to vote for the measure, it does not bind anyone's party, and a long list of cosponsors is a measure of attention rather than of prospects.

How long has it been in play?

It was introduced on July 14, 2026, 58 days ago. The most recent recorded action was 58 days ago, on July 14, 2026.

Measures do not carry over. Anything the 119th Congress has not finished by January 3, 2027 dies when the term ends, and has to be introduced again from the start in the next Congress.

Every answer above is assembled from this measure's own record on Congress.gov and from published counts of what Congress has passed before. Civibrief does not predict outcomes and takes no position on any measure.

Vote history

  1. House
    In committee, no floor vote yet
  2. Senate
    Awaits House passage
  3. President
    Awaits both chambers
No recorded votes yet
No roll call in this Congress cites this bill. Most bills die in committee without ever reaching a recorded floor vote.